logo-mobile
  • About
    ▼
    • Mission
    • Technology
    • Team
    • Investors
    • Legal
  • Technology
    ▼
    • Technology Story
    • How It Works
    • Targeted Impact
    • Applications
  • Pipeline
    ▼
    • Development
    • Pipeline Objectives
    • Featured Publications
  • News
    ▼
    • Press Releases
    • Media Coverage
    • Events
  • Logo
  • Partners
  • Careers
    ▼
    • Open Positions
  • Contact
  • Search
  • About
    • Mission
    • Technology
    • Team
    • Investors
    • Legal
  • Technology
    • Technology Story
    • How It Works
    • Targeted Impact
    • Applications
  • Pipeline
    • Development
    • Pipeline Objectives
    • Featured Publications
  • News
    • Press Releases
    • Media Coverage
    • Events
  • Logo
  • Partners
  • Careers
    • Open Positions
  • Contact
  • Search

how can we help?

AACR 2019 Poster – Tumor-selective CBX-11 (alphalex™-rucaparib) allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors

https://www.cybrexa.com/wp-content/uploads/2019/04/Cybrexa-Poster-2981-AACR-Mtg-Atlanta-Mar2019-002.pdf

 

Post navigation

Previous PostPrevious DNA Damage Response Therapeutics Summit
Next PostNext Cybrexa to present at the PARP and DDR Inhibitors Summit in Boston January 28-30

Recent Comments

    Archives

    Categories

    • Board of directors
    • Management Team
    • Scientific Advisors

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    about

    about

    • Mission
    • technology
    • team

    Technology

    Technology

    • technology story
    • targeted impact
    • how it works
    • applications

    pipeline

    pipeline

    • Development
    • Pipeline Objectives
    • Featured Publications

    news

    news

    • press releases
    • media coverage
    • events

    partners

    partners

    careers

    careers

    • open positions

    Contact us

    • legal

    © 2018 Cybrexa | All Rights Reserved